Clinical Trials Browser

Phase 2/3 × Standard of Care × 1 year × Clear all

NCT07155187 2026-03-11

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT07005102 2026-01-23

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Neoplasms

NCT03870750 2026-01-12

Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

Phase 2/3 Terminated

Other hematologic neoplasm

Hematologic Neoplasms

NCT07241715 2025-11-21

CONVERGENCE

Phase 2/3 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT06175273 2025-09-18

POINT

Phase 2/3 Completed

Muscular Atrophy, Neoplasms, Child Nutrition Disorders